- Clinical Pipeline
- Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
- Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
- ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- Partnered Products and Programs
- Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- Truqap™ PKB/Akt Inhibitor (Oncology)
- Multiple Targets and Therapeutic Areas
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation
Our partners are advancing several compounds in clinical trials that were the outcome of previous drug discovery collaborations with Astex including three drugs that have now been approved. The responsibility for developing these products is with our partners.
Discovery | Phase 1 | Phase 2 | Phase 3 | Marketed |
---|
Kisqali® (ribociclib)
CDK4/6 inhibitor (Oncology)
Partner: Novartis
. | . | . | . | . |
Balversa® (erdafitinib)
FGFr inhibitor (Oncology)
Partner: Janssen
. | . | . | . | . |
Truqap™ (capivasertib)
PKB/Akt Inhibitor (Oncology)
Partner: AstraZeneca
. | . | . | . | . |
. | . | . | . |
Other mutants:
. |
SHP2 (Oncology)
Partner: MSD and Taiho
. | . |
P53 (Oncology)
Partner: MSD
. |